Reena Ranpuria, MD
Nephrology · Greenbelt
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Capital Nephrology, PC · 9 clinicians in this group
Hospitals listed: 212552 · 212590 · 212622 · 212710 · Adventist Healthcare White Oak Medical Center · Holy Cross Hospital · Luminis Health Doctors Community Medical Ctr, Inc. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Ranpuria’s office at (301) 345-2412 to ask if they take your plan before you enroll.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Adventist Healthcare White Oak Medical CenterSilver Spring, MDAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Adventist Healthcare, which runs 6 hospitals in 2 statesPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.329, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Holy Cross HospitalSilver Spring, MDAcute Care Hospital · Voluntary non-profit - Church · No emergency department · Birthing-friendlyPart of Trinity Health, which runs 105 hospitals in 16 statesPatients rate it 3 of 5 · 66% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.417, Oct 2024 – Sep 2025
- Luminis Health Doctors Community Medical Ctr, IncLanham, MDAcute Care Hospital · Proprietary · Has an emergency departmentPart of Luminis Health, which runs 3 hospitalsPatients rate it 2 of 5 · 61% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.562, Oct 2024 – Sep 2025
See every measure and the patient survey for Adventist Healthcare White Oak Medical Center
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 7 the same, 2 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.329 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.13 (0.13 to 2.12) · 930 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.08 (0.79 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 193.49 (143.03 to 243.95) · 91 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 161 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.9 · 149 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13.7 · 167 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.4 · 417 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.1 · 614 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.7 · 185 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 2,281 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.14 (0 to 0.34) · 7,072 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.05 to 0.44) · 7,604 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.71 (2.56 to 6.86) · 1,402 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.51 (0.06 to 2.96) · 490 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (0.5 to 3.5) · 1,230 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.43 (0.88 to 11.97) · 542 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.51 (2.83 to 10.19) · 507 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.66 (0.18 to 3.15) · 217 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.94 (0.32 to 1.57) · 6,115 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.1 · 30 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.212 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.9 · 216 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.1 · 461 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 36.2 · 245 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -2 · 510 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 27.3 · 626 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.6 · 569 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 26 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.1 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 147 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (10.4 to 19) · 70 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 439 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,433 patients answered, 15% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 4 |
| Recommend hospital | 4 |
| Room was "always" clean | 79% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 74% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 62% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 51% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Holy Cross Hospital
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 3 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.417 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.74 (0 to 1.65) · 1,281 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1 (0.7 to 1.31) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 168.64 (122.7 to 214.58) · 111 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.1 · 147 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12 · 109 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12.5 · 294 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.9 · 484 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 257 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.9 · 3,336 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,462 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.08 to 0.46) · 6,733 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.21 (1.21 to 5.22) · 1,399 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.82 (0.22 to 3.42) · 635 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.66 (0.2 to 3.12) · 1,381 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.63 (2.77 to 16.49) · 628 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.09 (0.56 to 7.63) · 601 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.88 (0.43 to 3.32) · 448 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.86 (0.26 to 1.45) · 5,788 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 50 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.293 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.994 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.831 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 1.874 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.654 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.2 · 75 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.6 · 546 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 70.3 · 69 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 19.4 · 317 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 45.6 · 468 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.9 · 650 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.6 · 47 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 218 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (9.5 to 17.1) · 32 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.4) · 405 cases | No different | Jan 2024 – Dec 2024 |
What patients said (3,841 patients answered, 35% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 3 |
| Room was "always" clean | 67% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 62% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 67% |
| Nurses "always" treated them with courtesy and respect | 79% |
| "Always" quiet at night | 55% |
| "YES", patients would definitely recommend the hospital | 66% |
| Staff "always" explained possible side effects | 37% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
See every measure and the patient survey for Luminis Health Doctors Community Medical Ctr, Inc
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 1 better, 4 the same, 2 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.562 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.86 (0 to 1.85) · 1,053 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.09 (0.73 to 1.45) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 168.75 (122.04 to 215.45) · 67 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8 · 158 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.7 · 37 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.3 · 459 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.4 · 425 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.7 · 287 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 2,445 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 6,784 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 6,843 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5 (2.79 to 7.21) · 805 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.61 (0 to 3.31) · 232 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.19 (0.62 to 3.77) · 791 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.38 (2.56 to 20.19) · 253 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.25 (2.18 to 10.31) · 240 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.99 (0.5 to 3.47) · 248 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.51 (0 to 1.17) · 5,265 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.3 · 54 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.886 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.206 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.617 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.035 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21 · 657 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -2 · 580 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 11.6 · 442 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.7 · 561 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 7.2 · 51 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.5 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.6 (9.3 to 17.1) · 118 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.6 to 1.2) · 299 cases | No different | Jan 2024 – Dec 2024 |
What patients said (919 patients answered, 14% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 3 |
| Recommend hospital | 2 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 71% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 64% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 66% |
| Nurses "always" listened carefully | 68% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 58% |
| "YES", patients would definitely recommend the hospital | 61% |
| Staff "always" explained possible side effects | 41% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
Original Medicare doctor bills
$209,860
Medicare paid this office $209,860 for 407 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Dialysis services, 4 or more physician visits per month (20 years or older) | 31 | $72,894 | $313 |
| Home dialysis services per month (20 years or older) | 30 | $36,179 | $262 |
| Return visit (30+ min) | 188 | $27,272 | $72 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 128 | $20,061 | $70 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 32 | $19,222 | $263 |
See all 12 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 31 | $72,894 | $313 |
| Home dialysis services per month (20 years or older) | 30 | $36,179 | $262 |
| Return visit (30+ min) | 188 | $27,272 | $72 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 128 | $20,061 | $70 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 32 | $19,222 | $263 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 42 | $5,008 | $116 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 175 | $4,402 | $14 |
| Dialysis services, 1 physician visit per month (20 years or older) | 11 | $3,831 | $182 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 49 | $3,360 | $44 |
| New patient visit (45+ min) | 21 | $3,081 | $147 |
| Short return visit (20+ min) | 38 | $2,615 | $69 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 16 | $2,008 | $106 |
Who their Medicare patients are
407 Original Medicare patients in 2024. Average age 74 · Under 65 14% · 85 and older 16% · Women 50% · Also on Medicaid 29% · Health risk score 4.13. Above the middle of the specialty; the typical nephrology clinician is at 4.01.
Conditions among them: High blood pressure 75% · Chronic kidney disease 75% · Diabetes 70% · Coronary heart disease 43% · Heart failure 40% · Atrial fibrillation 28% · Depression 22% · COPD 21% · Stroke 20% · Dementia 19% · Cancer 17%.
The office billed $385,351, Medicare allowed $273,713 and paid $209,860; for 2,863 services of 20 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 407 | 2,863 | 74 | 4.13 | $385,351 | $209,860 |
| 2023 | 503 | 3,374 | 73 | 4.51 | $486,190 | $261,395 |
| 2022 | 596 | 2,835 | 73 | 4.47 | $532,920 | $303,509 |
| 2021 | 571 | 2,681 | 72 | 4.24 | $536,560 | $311,601 |
| 2020 | 546 | 3,213 | 71 | 4.62 | $561,320 | $288,342 |
| 2019 | 526 | 3,496 | 72 | 4.59 | $559,975 | $284,393 |
| 2018 | 491 | 3,648 | 71 | 4.49 | $492,020 | $240,577 |
| 2017 | 449 | 2,966 | 70 | 5.33 | $421,965 | $216,366 |
| 2016 | 388 | 2,777 | 72 | 4.75 | $360,235 | $191,340 |
| 2015 | 368 | 2,067 | 71 | 4.64 | $314,875 | $164,828 |
| 2014 | 385 | 2,066 | 71 | 4.67 | $330,390 | $171,352 |
| 2013 | 379 | 1,664 | 70 | 5.35 | $347,839 | $175,891 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 13 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 58 | $94,646 | $314 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 163 | $34,189 | $69 |
| Home dialysis services per month (20 years or older) | 34 | $31,288 | $265 |
| Return visit (30+ min) | 195 | $30,410 | $73 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 44 | $29,677 | $256 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 90 | $11,140 | $115 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 12 | $9,061 | None |
| Dialysis services, 1 physician visit per month (20 years or older) | 22 | $7,441 | $181 |
| New patient visit (45+ min) | 34 | $4,253 | $125 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 47 | $2,932 | $42 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 16 | $2,225 | $106 |
| New patient visit (30+ min) | 13 | $1,256 | $97 |
| Injection of drug or substance under skin or into muscle | 12 | $604 | $13 |
2022: 10 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 49 | $89,331 | $318 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 206 | $42,379 | $63 |
| Home dialysis services per month (20 years or older) | 47 | $41,332 | $272 |
| Return visit (30+ min) | 202 | $39,943 | $109 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 64 | $38,814 | $264 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 111 | $14,923 | $120 |
| Dialysis services, 1 physician visit per month (20 years or older) | 34 | $13,585 | $181 |
| New patient visit (45+ min) | 53 | $6,793 | $128 |
| Telephone medical discussion with physician, 21-30 minutes | 64 | $4,939 | $69 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 77 | $4,190 | $35 |
2021: 9 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 49 | $120,097 | $324 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 224 | $36,869 | $66 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 44 | $32,384 | $268 |
| Return visit (30+ min) | 142 | $25,952 | $116 |
| Telephone medical discussion with physician, 21-30 minutes | 140 | $24,263 | $107 |
| Dialysis services, 1 physician visit per month (20 years or older) | 24 | $15,969 | $184 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 117 | $15,357 | $122 |
| New patient visit (45+ min) | 45 | $6,529 | $145 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 121 | $6,460 | $35 |
2020: 13 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 57 | $120,491 | $261 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 221 | $37,434 | $68 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 50 | $25,415 | $219 |
| Telephone medical discussion with physician, 21-30 minutes | 117 | $18,939 | $99 |
| Dialysis services, 1 physician visit per month (20 years or older) | 34 | $13,502 | $171 |
| Return visit (30+ min) | 106 | $13,164 | $84 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 95 | $12,730 | $130 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 149 | $9,774 | $38 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 25 | $4,811 | $192 |
| New patient visit (45+ min) | 18 | $2,754 | $153 |
| Telephone medical discussion with physician, 11-20 minutes | 30 | $1,886 | $59 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 11 | $1,029 | $94 |
| Short return visit (20+ min) | 13 | $561 | $40 |
2019: 15 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 61 | $115,246 | $247 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 55 | $35,658 | $209 |
| Return visit (30+ min) | 174 | $33,446 | $90 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 172 | $25,157 | $65 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 15 | $12,957 | None |
| Home dialysis services per month (20 years or older) | 18 | $12,853 | $207 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 82 | $11,092 | $117 |
| Dialysis services, 1 physician visit per month (20 years or older) | 27 | $9,129 | $166 |
| New patient visit (45+ min) | 59 | $7,825 | $133 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 129 | $7,611 | $35 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 38 | $6,951 | $178 |
| Short return visit (20+ min) | 28 | $1,810 | $57 |
| Hemodialysis procedure with physician evaluation | 15 | $1,753 | $65 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 13 | $1,175 | $90 |
| Injection of drug or substance under skin or into muscle | 15 | $635 | $15 |
2018: 14 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 49 | $71,145 | $237 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 58 | $32,056 | $200 |
| Return visit (30+ min) | 150 | $28,699 | $85 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 167 | $23,387 | $62 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 14 | $17,539 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 87 | $15,281 | $170 |
| Dialysis services, 1 physician visit per month (20 years or older) | 40 | $12,394 | $153 |
| New patient visit (45+ min) | 47 | $6,280 | $134 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 93 | $5,142 | $33 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 37 | $4,547 | $117 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 32 | $4,368 | $87 |
| Hemodialysis procedure with physician evaluation | 34 | $4,005 | $62 |
| Short return visit (20+ min) | 35 | $2,080 | $55 |
| Injection of drug or substance under skin or into muscle | 14 | $869 | $18 |
2017: 13 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 43 | $54,225 | $244 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 62 | $30,080 | $203 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 182 | $27,759 | $63 |
| Return visit (30+ min) | 135 | $24,622 | $88 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 111 | $21,146 | $175 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 14 | $12,503 | None |
| Dialysis services, 1 physician visit per month (20 years or older) | 33 | $11,385 | $158 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 61 | $8,870 | $91 |
| Hemodialysis procedure with physician evaluation | 41 | $4,709 | $63 |
| New patient visit (45+ min) | 31 | $4,211 | $136 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 77 | $3,439 | $34 |
| Short return visit (20+ min) | 17 | $1,097 | $65 |
| Injection of drug or substance under skin or into muscle | 13 | $971 | $24 |
2016: 12 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 47 | $64,032 | $237 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 161 | $26,114 | $62 |
| Return visit (30+ min) | 133 | $26,067 | $85 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 47 | $22,257 | $202 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 92 | $18,227 | $169 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 13 | $11,680 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 43 | $5,780 | $89 |
| Dialysis services, 1 physician visit per month (20 years or older) | 16 | $4,811 | $155 |
| New patient visit (45+ min) | 25 | $3,498 | $140 |
| Hemodialysis procedure with physician evaluation | 25 | $2,227 | $62 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 45 | $2,122 | $34 |
| Injection of drug or substance under skin or into muscle | 13 | $1,164 | $23 |
2015: 12 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 38 | $45,342 | $240 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 136 | $23,178 | $62 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 41 | $19,988 | $204 |
| Return visit (30+ min) | 120 | $19,391 | $87 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 90 | $17,126 | $175 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 63 | $12,313 | $89 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 16 | $5,757 | None |
| New patient visit (45+ min) | 31 | $4,087 | $132 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 74 | $3,927 | $34 |
| Dialysis services, 1 physician visit per month (20 years or older) | 14 | $3,249 | $155 |
| Hemodialysis procedure with physician evaluation | 27 | $2,366 | $62 |
| Injection of drug or substance under skin or into muscle | 16 | $712 | $23 |
2014: 11 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 43 | $40,586 | $243 |
| Return visit (30+ min) | 127 | $24,687 | $88 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 42 | $21,963 | $207 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 139 | $21,857 | $62 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 102 | $19,097 | $172 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 60 | $10,765 | $89 |
| New patient visit (45+ min) | 40 | $5,663 | $142 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 87 | $4,948 | $34 |
| Dialysis services, 1 physician visit per month (20 years or older) | 14 | $4,377 | $162 |
| Hemodialysis procedure with physician evaluation | 37 | $3,812 | $62 |
| Short return visit (20+ min) | 15 | $842 | $56 |
2013: 10 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 61 | $57,113 | $239 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 168 | $26,519 | $60 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 123 | $22,898 | $170 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 49 | $21,230 | $204 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 81 | $12,995 | $85 |
| Return visit (30+ min) | 84 | $12,849 | $78 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 84 | $5,065 | $33 |
| Hemodialysis procedure with physician evaluation | 43 | $4,703 | $61 |
| Dialysis services, 1 physician visit per month (20 years or older) | 16 | $3,832 | $153 |
| New patient visit (45+ min) | 24 | $3,358 | $140 |
Medicaid work
$5,863 in 2024
Medicaid paid $5,863 for 84 billed services this clinician did in 2024, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 43 | $3,306 |
| Return visit (30+ min) | 12 | $1,364 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 29 | $1,193 |
| 2024 | 84 | 3 | 14 | $5,863 |
| 2023 | 472 | 4 | 20 | $39,555 |
| 2022 | 468 | 5 | 21 | $22,044 |
| 2021 | 390 | 2 | 20 | $20,589 |
| 2020 | 351 | 3 | 15 | $26,256 |
| 2019 | 85 | 3 | 16 | $9,006 |
See the largest Medicaid services in earlier years
2023
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 121 | $17,654 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 228 | $10,656 |
| Return visit (30+ min) | 110 | $9,807 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 13 | $1,438 |
2022
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 319 | $11,946 |
| Return visit (30+ min) | 83 | $4,549 |
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 29 | $4,146 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 15 | $969 |
| SBSQ HOSPITAL IP/OBS CARE SF/LOW MDM 25 MINUTES | 22 | $434 |
2021
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 324 | $13,791 |
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 66 | $6,798 |
2020
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 117 | $17,543 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 190 | $5,770 |
| Short return visit (20+ min) | 44 | $2,943 |
2019
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 2-3 face-to-face visits by a physician or other qualified health care professional per month | 56 | $6,389 |
| Return visit (30+ min) | 16 | $1,690 |
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month | 13 | $927 |
Drugs they prescribed that Part D paid
$334,273
Pharmacies billed $334,273 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
890 generic and fewer than 11 brand-name prescriptions · $334,273 in drug cost · 19 antibiotic prescriptions to 17 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xphozah | 16 | $61,034 | $3,815 |
| Veltassa | 33 | $48,806 | $1,479 |
| Velphoro | 12 | $46,994 | $3,916 |
| Farxiga | 40 | $35,572 | $889 |
| Kerendia | 17 | $29,727 | $1,749 |
See all 28 drugs
| Xphozah | 16 | $61,034 | $3,815 |
| Veltassa | 33 | $48,806 | $1,479 |
| Velphoro | 12 | $46,994 | $3,916 |
| Farxiga | 40 | $35,572 | $889 |
| Kerendia | 17 | $29,727 | $1,749 |
| Rayaldee | 11 | $22,420 | $2,038 |
| Sevelamer Carbonate | 42 | $18,014 | $429 |
| Prosol | 42 | $5,426 | $129 |
| Calcitriol | 127 | $3,175 | $25 |
| Calcium Acetate | 17 | $2,739 | $161 |
| Hydralazine | 44 | $1,280 | $29 |
| Nifedipine Er | 17 | $869 | $51 |
| Midodrine | 20 | $790 | $39 |
| Gentamicin Sulfate | 16 | $769 | $48 |
| Doxazosin Mesylate | 22 | $733 | $33 |
| Amlodipine Besylate | 97 | $633 | $7 |
| Losartan | 61 | $503 | $8 |
| Tamsulosin | 24 | $434 | $18 |
| Lidocaine-Prilocaine | 13 | $321 | $25 |
| Furosemide | 53 | $280 | $5 |
| Allopurinol | 26 | $278 | $11 |
| Metoprolol | 24 | $276 | $12 |
| Eplerenone | 12 | $155 | $13 |
| Carvedilol | 18 | $149 | $8 |
| Lisinopril | 27 | $141 | $5 |
| Clonidine | 34 | $125 | $4 |
| Metoprolol | 19 | $106 | $6 |
| Hydrochlorothiazide | 21 | $103 | $5 |
Year by year
| 2024 | 1,097 | 171 | None | None | $334,273 |
| 2023 | 866 | 152 | None | None | $357,467 |
| 2022 | 703 | 140 | None | 16% | $324,887 |
| 2021 | 650 | 114 | None | 26% | $473,040 |
| 2020 | 650 | 117 | None | None | $1,424,537 |
| 2019 | 824 | 144 | None | 17% | $1,136,275 |
| 2018 | 1,059 | 184 | None | None | $2,072,903 |
| 2017 | 1,287 | 205 | None | 31% | $953,273 |
| 2016 | 1,254 | 132 | None | None | $875,640 |
| 2015 | 1,228 | 127 | 2% (24) | 45% | $447,736 |
| 2014 | 1,284 | 135 | 1% (18) | 36% | $324,935 |
| 2013 | 1,104 | 109 | None | 39% | $236,320 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 24 drugs
| Velphoro | 15 | $78,247 | $5,216 |
| Veltassa | 32 | $48,478 | $1,515 |
| Rayaldee | 16 | $32,354 | $2,022 |
| Kerendia | 24 | $23,467 | $978 |
| Sevelamer Carbonate | 22 | $7,185 | $327 |
| Prosol | 44 | $6,064 | $138 |
| Calcium Acetate | 18 | $3,632 | $202 |
| Calcitriol | 96 | $3,439 | $36 |
| Hydralazine | 33 | $1,349 | $41 |
| Nifedipine Er | 18 | $1,328 | $74 |
| Gentamicin Sulfate | 12 | $681 | $57 |
| Midodrine | 20 | $670 | $34 |
| Tamsulosin | 21 | $619 | $29 |
| Amlodipine Besylate | 65 | $506 | $8 |
| Allopurinol | 28 | $475 | $17 |
| Losartan | 31 | $461 | $15 |
| Doxazosin Mesylate | 16 | $427 | $27 |
| Carvedilol | 18 | $349 | $19 |
| Clonidine | 19 | $338 | $18 |
| Furosemide | 43 | $309 | $7 |
| Metoprolol | 13 | $292 | $22 |
| Prednisone | 13 | $135 | $10 |
| Lisinopril | 22 | $121 | $5 |
| Hydrochlorothiazide | 12 | $69 | $6 |
2022: 20 drugs
| Velphoro | 19 | $91,451 | $4,813 |
| Veltassa | 35 | $42,366 | $1,210 |
| Sevelamer Carbonate | 16 | $22,634 | $1,415 |
| Farxiga | 11 | $17,691 | $1,608 |
| Calcium Acetate | 27 | $8,516 | $315 |
| Midodrine | 25 | $2,455 | $98 |
| Nifedipine Er | 21 | $2,206 | $105 |
| Calcitriol | 47 | $1,861 | $40 |
| Hydralazine | 41 | $1,517 | $37 |
| Amlodipine Besylate | 57 | $716 | $13 |
| Carvedilol | 33 | $629 | $19 |
| Clonidine | 23 | $616 | $27 |
| Allopurinol | 23 | $383 | $17 |
| Tamsulosin | 19 | $371 | $20 |
| Doxazosin Mesylate | 13 | $306 | $24 |
| Furosemide | 45 | $272 | $6 |
| Eplerenone | 12 | $215 | $18 |
| Losartan | 16 | $170 | $11 |
| Hydrochlorothiazide | 11 | $66 | $6 |
| Lisinopril | 11 | $61 | $6 |
2021: 22 drugs
| Jynarque | 11 | $187,105 | $17,010 |
| Auryxia | 32 | $73,170 | $2,287 |
| Veltassa | 31 | $26,640 | $859 |
| Sevelamer Carbonate | 20 | $16,501 | $825 |
| Farxiga | 15 | $15,111 | $1,007 |
| Calcium Acetate | 28 | $5,637 | $201 |
| Midodrine | 16 | $1,519 | $95 |
| Calcitriol | 35 | $1,292 | $37 |
| Nifedipine Er | 14 | $783 | $56 |
| Doxazosin Mesylate | 17 | $633 | $37 |
| Clonidine | 18 | $507 | $28 |
| Amlodipine Besylate | 47 | $492 | $10 |
| Metoprolol | 16 | $463 | $29 |
| Tamsulosin | 16 | $436 | $27 |
| Eplerenone | 13 | $408 | $31 |
| Hydralazine | 25 | $394 | $16 |
| Carvedilol | 20 | $327 | $16 |
| Furosemide | 38 | $327 | $9 |
| Allopurinol | 16 | $268 | $17 |
| Lisinopril | 30 | $220 | $7 |
| Losartan | 12 | $210 | $18 |
| Hydrochlorothiazide | 18 | $96 | $5 |
2020: 20 drugs
| Jynarque | 13 | $189,750 | $14,596 |
| Auryxia | 25 | $61,474 | $2,459 |
| Sevelamer Carbonate | 12 | $7,921 | $660 |
| Calcium Acetate | 35 | $5,765 | $165 |
| Midodrine | 34 | $2,848 | $84 |
| Calcitriol | 30 | $1,423 | $47 |
| Metoprolol | 26 | $1,086 | $42 |
| Nifedipine Er | 23 | $629 | $27 |
| Hydralazine | 23 | $589 | $26 |
| Doxazosin Mesylate | 15 | $589 | $39 |
| Tamsulosin | 22 | $463 | $21 |
| Clonidine | 18 | $392 | $22 |
| Amlodipine Besylate | 37 | $367 | $10 |
| Carvedilol | 16 | $333 | $21 |
| Atorvastatin | 17 | $283 | $17 |
| Hydrochlorothiazide | 27 | $247 | $9 |
| Furosemide | 36 | $225 | $6 |
| Allopurinol | 14 | $213 | $15 |
| Lisinopril | 23 | $185 | $8 |
| Azithromycin | 12 | $75 | $6 |
2019: 25 drugs
| Acthar | 12 | $967,898 | $80,658 |
| Auryxia | 22 | $54,402 | $2,473 |
| Sevelamer Carbonate | 16 | $21,367 | $1,335 |
| Calcium Acetate | 37 | $5,311 | $144 |
| Metoprolol | 32 | $1,624 | $51 |
| Calcitriol | 38 | $1,332 | $35 |
| Nifedipine Er | 15 | $1,263 | $84 |
| Metolazone | 17 | $1,029 | $61 |
| Eplerenone | 12 | $877 | $73 |
| Hydralazine | 28 | $844 | $30 |
| Doxazosin Mesylate | 17 | $557 | $33 |
| Carvedilol | 19 | $540 | $28 |
| Allopurinol | 27 | $466 | $17 |
| Potassium Chloride | 15 | $457 | $30 |
| Midodrine | 13 | $449 | $35 |
| Amlodipine Besylate | 64 | $449 | $7 |
| Clonidine | 19 | $389 | $20 |
| Atorvastatin | 15 | $350 | $23 |
| Lisinopril | 39 | $282 | $7 |
| Tamsulosin | 19 | $278 | $15 |
| Furosemide | 45 | $271 | $6 |
| Metoprolol | 21 | $203 | $10 |
| Losartan | 14 | $182 | $13 |
| Hydrochlorothiazide | 22 | $158 | $7 |
| Gabapentin | 19 | $136 | $7 |
2018: 28 drugs
| H.P. Acthar | 23 | $1,864,718 | $81,075 |
| Auryxia | 38 | $47,929 | $1,261 |
| Renvela | 23 | $38,496 | $1,674 |
| Sevelamer Carbonate | 26 | $33,491 | $1,288 |
| Calcium Acetate | 50 | $3,833 | $77 |
| Prosol | 21 | $2,742 | $131 |
| Colchicine | 15 | $2,605 | $174 |
| Calcitriol | 48 | $1,220 | $25 |
| Hydralazine | 71 | $1,078 | $15 |
| Metoprolol | 19 | $691 | $36 |
| Tamsulosin | 28 | $590 | $21 |
| Amlodipine Besylate | 64 | $512 | $8 |
| Doxazosin Mesylate | 20 | $493 | $25 |
| Pravastatin | 17 | $396 | $23 |
| Diltiazem 24hr Er (Cd) | 11 | $377 | $34 |
| Atorvastatin | 29 | $358 | $12 |
| Allopurinol | 21 | $354 | $17 |
| Potassium Chloride | 13 | $296 | $23 |
| Losartan | 37 | $288 | $8 |
| Furosemide | 57 | $271 | $5 |
| Clonidine | 25 | $256 | $10 |
| Losartan-Hydrochlorothiazide | 22 | $209 | $10 |
| Carvedilol | 18 | $189 | $11 |
| Lisinopril | 25 | $185 | $7 |
| Metoprolol | 18 | $153 | $8 |
| Pantoprazole | 18 | $151 | $8 |
| Hydrochlorothiazide | 19 | $111 | $6 |
| Gabapentin | 17 | $66 | $4 |
2017: 29 drugs
| Sensipar | 95 | $190,574 | $2,006 |
| Renvela | 68 | $144,840 | $2,130 |
| Velphoro | 13 | $44,824 | $3,448 |
| Fosrenol | 14 | $14,843 | $1,060 |
| Prosol | 38 | $6,236 | $164 |
| Calcium Acetate | 48 | $5,256 | $109 |
| Lantus | 14 | $3,480 | $249 |
| Calcitriol | 70 | $3,078 | $44 |
| Metolazone | 21 | $1,710 | $81 |
| Hydralazine | 49 | $958 | $20 |
| Midodrine | 12 | $898 | $75 |
| Metoprolol | 27 | $801 | $30 |
| Carvedilol | 35 | $617 | $18 |
| Atorvastatin | 46 | $590 | $13 |
| Losartan | 36 | $551 | $15 |
| Clonidine | 32 | $535 | $17 |
| Diltiazem 24hr Er | 19 | $529 | $28 |
| Tamsulosin | 16 | $523 | $33 |
| Amlodipine Besylate | 54 | $494 | $9 |
| Allopurinol | 21 | $389 | $19 |
| Furosemide | 52 | $381 | $7 |
| Doxazosin Mesylate | 11 | $338 | $31 |
| Pantoprazole | 32 | $295 | $9 |
| Levothyroxine | 11 | $250 | $23 |
| Lisinopril | 36 | $190 | $5 |
| Gabapentin | 32 | $186 | $6 |
| Metoprolol | 20 | $140 | $7 |
| Hydrochlorothiazide | 17 | $76 | $4 |
| Alprazolam | 11 | $42 | $4 |
2016: 31 drugs
| Sensipar | 99 | $162,158 | $1,638 |
| Renvela | 82 | $158,485 | $1,933 |
| Fosrenol | 23 | $23,656 | $1,029 |
| Prosol | 75 | $12,945 | $173 |
| Calcium Acetate | 38 | $6,239 | $164 |
| Symbicort | 12 | $3,566 | $297 |
| Calcitriol | 70 | $2,408 | $34 |
| Metolazone | 31 | $1,602 | $52 |
| Midodrine | 17 | $1,423 | $84 |
| Hydroxychloroquine Sulfate | 12 | $940 | $78 |
| Hydralazine | 42 | $922 | $22 |
| Metoprolol | 22 | $550 | $25 |
| Doxazosin Mesylate | 12 | $452 | $38 |
| Lidocaine-Prilocaine | 12 | $452 | $38 |
| Amlodipine Besylate | 64 | $408 | $6 |
| Lactulose | 17 | $332 | $20 |
| Atorvastatin | 28 | $326 | $12 |
| Pantoprazole | 32 | $323 | $10 |
| Metoclopramide | 24 | $307 | $13 |
| Carvedilol | 58 | $281 | $5 |
| Mycophenolate Mofetil | 12 | $238 | $20 |
| Furosemide | 34 | $229 | $7 |
| Allopurinol | 16 | $216 | $14 |
| Gabapentin | 32 | $182 | $6 |
| Zolpidem | 12 | $179 | $15 |
| Lisinopril | 29 | $177 | $6 |
| Clonidine | 12 | $111 | $9 |
| Azithromycin | 15 | $94 | $6 |
| Escitalopram | 13 | $85 | $7 |
| Alprazolam | 16 | $62 | $4 |
| Hydrochlorothiazide | 17 | $57 | $3 |
2015: 34 drugs
| Renvela | 103 | $158,458 | $1,538 |
| Sensipar | 83 | $120,384 | $1,450 |
| Velphoro | 11 | $29,591 | $2,690 |
| Fosrenol | 22 | $27,994 | $1,272 |
| Prosol | 138 | $23,759 | $172 |
| Lyrica | 14 | $5,376 | $384 |
| Calcium Acetate | 42 | $5,354 | $127 |
| Symbicort | 16 | $4,451 | $278 |
| Crestor | 12 | $2,951 | $246 |
| Calcitriol | 50 | $2,261 | $45 |
| Kionex | 13 | $1,199 | $92 |
| Hydroxychloroquine Sulfate | 11 | $969 | $88 |
| Metolazone | 15 | $869 | $58 |
| Hydralazine | 23 | $674 | $29 |
| Doxazosin Mesylate | 13 | $669 | $51 |
| Metoprolol | 28 | $611 | $22 |
| Midodrine | 14 | $457 | $33 |
| Lactulose | 19 | $366 | $19 |
| Oracit | 16 | $252 | $16 |
| Metoclopramide | 26 | $225 | $9 |
| Amlodipine Besylate | 29 | $217 | $7 |
| Carvedilol | 28 | $212 | $8 |
| Pantoprazole | 22 | $212 | $10 |
| Omeprazole | 20 | $184 | $9 |
| Tramadol | 18 | $172 | $10 |
| Allopurinol | 14 | $144 | $10 |
| Furosemide | 34 | $128 | $4 |
| Lisinopril | 21 | $95 | $5 |
| Alprazolam | 13 | $91 | $7 |
| Clonidine | 13 | $76 | $6 |
| Zolpidem | 12 | $61 | $5 |
| Azithromycin | 11 | $55 | $5 |
| Hydrochlorothiazide | 19 | $49 | $3 |
| Gabapentin | 13 | $41 | $3 |
2014: 36 drugs
| Renvela | 101 | $112,995 | $1,119 |
| Sensipar | 65 | $79,887 | $1,229 |
| Fosrenol | 18 | $30,737 | $1,708 |
| Sevelamer Carbonate | 14 | $15,018 | $1,073 |
| Prosol | 54 | $13,960 | $259 |
| Calcium Acetate | 52 | $6,818 | $131 |
| Nasonex | 11 | $1,842 | $167 |
| Doxazosin Mesylate | 49 | $1,665 | $34 |
| Calcitriol | 47 | $1,378 | $29 |
| Hydralazine | 42 | $1,218 | $29 |
| Labetalol | 14 | $918 | $66 |
| Metoprolol | 29 | $829 | $29 |
| Midodrine | 16 | $728 | $46 |
| Metolazone | 18 | $636 | $35 |
| Pantoprazole | 34 | $523 | $15 |
| Lactulose | 21 | $474 | $23 |
| Oracit | 25 | $391 | $16 |
| Pravastatin | 16 | $313 | $20 |
| Amlodipine Besylate | 35 | $298 | $9 |
| Atorvastatin | 30 | $286 | $10 |
| Levothyroxine | 21 | $256 | $12 |
| Omeprazole | 29 | $254 | $9 |
| Gabapentin | 21 | $238 | $11 |
| Montelukast | 12 | $236 | $20 |
| Diltiazem 24hr Er | 14 | $192 | $14 |
| Carvedilol | 28 | $188 | $7 |
| Clonidine | 17 | $157 | $9 |
| Isosorbide Mononitrate Er | 12 | $137 | $11 |
| Lisinopril | 25 | $129 | $5 |
| Simvastatin | 17 | $106 | $6 |
| Hydrochlorothiazide | 17 | $94 | $6 |
| Furosemide | 32 | $84 | $3 |
| Minoxidil | 13 | $73 | $6 |
| Allopurinol | 11 | $72 | $7 |
| Famotidine | 20 | $62 | $3 |
| Metoprolol | 13 | $48 | $4 |
2013: 28 drugs
| Renvela | 113 | $83,686 | $741 |
| Renagel | 46 | $51,382 | $1,117 |
| Sensipar | 47 | $40,264 | $857 |
| Fosrenol | 19 | $24,913 | $1,311 |
| Calcium Acetate | 45 | $5,497 | $122 |
| Diovan | 14 | $2,366 | $169 |
| Calcitriol | 50 | $2,188 | $44 |
| Clinisol | 17 | $1,833 | $108 |
| Hydralazine | 30 | $673 | $22 |
| Diltiazem 24hr Er | 12 | $631 | $53 |
| Atorvastatin | 23 | $616 | $27 |
| Labetalol | 20 | $599 | $30 |
| Pantoprazole | 53 | $592 | $11 |
| Ventolin Hfa | 14 | $583 | $42 |
| Doxazosin Mesylate | 52 | $532 | $10 |
| Oxybutynin Chloride Er | 11 | $452 | $41 |
| Oracit | 29 | $450 | $16 |
| Lisinopril | 48 | $301 | $6 |
| Amlodipine Besylate | 36 | $279 | $8 |
| Carvedilol | 30 | $274 | $9 |
| Omeprazole | 21 | $242 | $12 |
| Simvastatin | 35 | $223 | $6 |
| Lactulose | 14 | $219 | $16 |
| Furosemide | 36 | $162 | $5 |
| Minoxidil | 12 | $136 | $11 |
| Spironolactone | 12 | $91 | $8 |
| Metoprolol | 12 | $47 | $4 |
| Famotidine | 12 | $41 | $3 |
Money from drug and device companies
$1,705 in 2025
| 2025 | 20 | 76 | None | $1,705 |
| 2024 | 18 | 98 | None | $2,114 |
| 2023 | 22 | 95 | None | $2,321 |
| 2022 | 15 | 82 | None | $1,697 |
| 2021 | 14 | 63 | None | $1,218 |
| 2020 | 9 | 27 | None | $584 |
| 2019 | 9 | 42 | None | $966 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | Farxiga | $195 | 9 payments
|
| Mallinckrodt Hospital Products | Acthar | $190 | 7 payments
|
| Novartis Pharmaceuticals | Fabhalta | $168 | 13 payments
|
| Vifor Pharma | Veltassa | $162 | 7 payments
|
| Scpharmaceuticals | Furoscix | $116 | 4 payments
|
| Aurinia Pharma U.S. | Lupkynis | $103 | 4 payments
|
See all 76 published payments
| Otsuka Pharmaceutical Development & Commercialization | Meals · 2025-12-17 | None | $38 |
| Vifor Pharma | Meals · 2025-12-01 | Veltassa | $16 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-19 | Farxiga | $23 |
| Novartis Pharmaceuticals | Meals · 2025-11-18 | Fabhalta | $21 |
| Travere Therapeutics | Meals · 2025-11-17 | None | $24 |
| Recor Medical | Meals · 2025-11-11 | Paradise Ultrasound Renal Denervation System | $46 |
| OPKO Pharmaceuticals | Education · 2025-11-05 | Rayaldee | $22 |
| Mallinckrodt Hospital Products | Meals · 2025-10-21 | Acthar | $35 |
| Travere Therapeutics | Meals · 2025-10-15 | None | $27 |
| Akebia Therapeutics | Meals · 2025-10-14 | Auryxia | $29 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-13 | Farxiga | $23 |
| Novartis Pharmaceuticals | Meals · 2025-10-08 | Fabhalta | $18 |
| Scpharmaceuticals | Meals · 2025-10-06 | Furoscix | $30 |
| Aurinia Pharma U.S. | Meals · 2025-09-30 | Lupkynis | $25 |
| Vifor Pharma | Meals · 2025-09-16 | Veltassa | $19 |
| Ardelyx | Meals · 2025-09-15 | Ibsrela | $15 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-10 | Farxiga | $16 |
| GlaxoSmithKline | Meals · 2025-09-09 | Benlysta | $26 |
| Novartis Pharmaceuticals | Meals · 2025-09-02 | Fabhalta | $34 |
| Otsuka America Pharmaceutical | Meals · 2025-08-26 | Jynarque | $25 |
| Aurinia Pharma U.S. | Meals · 2025-08-18 | Lupkynis | $29 |
| Mallinckrodt Hospital Products | Meals · 2025-08-12 | Acthar | $40 |
| Scpharmaceuticals | Meals · 2025-08-11 | Furoscix | $26 |
| Novartis Pharmaceuticals | Meals · 2025-08-04 | Vanrafia | $20 |
| GlaxoSmithKline | Meals · 2025-07-30 | Benlysta | $35 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-29 | Farxiga | $19 |
| Scpharmaceuticals | Meals · 2025-07-23 | Furoscix | $31 |
| Fresenius USA Marketing | Meals · 2025-07-23 | Velphoro | $20 |
| OPKO Pharmaceuticals | Education · 2025-07-21 | Rayaldee | $21 |
| Ardelyx | Meals · 2025-07-14 | Ibsrela | $27 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-07 | Farxiga | $20 |
| Mallinckrodt Hospital Products | Meals · 2025-07-02 | Acthar | $36 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-25 | None | $31 |
| Calliditas Therapeutics US | Meals · 2025-06-24 | Tarpeyo | $21 |
| Fresenius USA Marketing | Meals · 2025-06-18 | Velphoro | $22 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-06-17 | Kerendia | $18 |
| Amgen | Meals · 2025-06-10 | Tavneos | $26 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-09 | Farxiga | $20 |
| Lilly USA | Meals · 2025-06-06 | Jardiance | $24 |
| Novartis Pharmaceuticals | Meals · 2025-06-04 | Vanrafia | $2 |
| Novartis Pharmaceuticals | Meals · 2025-06-04 | Vanrafia | $2 |
| Novartis Pharmaceuticals | Meals · 2025-06-04 | Vanrafia | $11 |
| Scpharmaceuticals | Meals · 2025-06-02 | Furoscix | $29 |
| GlaxoSmithKline | Meals · 2025-05-27 | Benlysta | $21 |
| Ardelyx | Meals · 2025-05-20 | Ibsrela | $18 |
| Vifor Pharma | Meals · 2025-05-13 | Veltassa | $25 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-05-08 | Kerendia | $15 |
| Akebia Therapeutics | Meals · 2025-05-06 | Vafseo | $23 |
| Akebia Therapeutics | Meals · 2025-05-05 | Vafseo | $31 |
| Novartis Pharmaceuticals | Meals · 2025-04-30 | Vanrafia | $13 |
| Novartis Pharmaceuticals | Meals · 2025-04-30 | Vanrafia | $1 |
| Novartis Pharmaceuticals | Meals · 2025-04-30 | Vanrafia | $2 |
| Aurinia Pharma U.S. | Meals · 2025-04-22 | Lupkynis | $22 |
| Kyowa Kirin | Meals · 2025-04-09 | Crysvita | $24 |
| Mallinckrodt Hospital Products | Meals · 2025-04-08 | Acthar | $33 |
| Vifor Pharma | Meals · 2025-04-07 | Veltassa | $28 |
| Amgen | Meals · 2025-04-02 | Krystexxa | $28 |
| Novartis Pharmaceuticals | Meals · 2025-03-31 | None | $16 |
| Novartis Pharmaceuticals | Meals · 2025-03-31 | None | $5 |
| Otsuka Pharmaceutical Development & Commercialization | Meals · 2025-03-19 | None | $21 |
| Mallinckrodt Hospital Products | Meals · 2025-03-18 | Acthar | $2 |
| Mallinckrodt Hospital Products | Meals · 2025-03-18 | Acthar | $7 |
| Ardelyx | Meals · 2025-03-17 | Ibsrela | $15 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-03-12 | Kerendia | $15 |
| Calliditas Therapeutics US | Meals · 2025-03-04 | Tarpeyo | $19 |
| Vifor Pharma | Meals · 2025-03-03 | Veltassa | $27 |
| Fresenius USA Marketing | Meals · 2025-02-27 | Velphoro | $23 |
| Mallinckrodt Hospital Products | Meals · 2025-02-25 | Acthar | $36 |
| Vifor Pharma | Meals · 2025-02-18 | Veltassa | $20 |
| Novartis Pharmaceuticals | Meals · 2025-02-11 | None | $24 |
| Ardelyx | Meals · 2025-02-05 | Ibsrela | $20 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-04 | Farxiga | $18 |
| Aurinia Pharma U.S. | Meals · 2025-02-04 | Lupkynis | $27 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-01-21 | Kerendia | $30 |
| Vifor Pharma | Meals · 2025-01-15 | Veltassa | $26 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-13 | Farxiga | $24 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $2,114
| Mallinckrodt Hospital Products | Acthar | $315 | 14 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $287 | 14 payments
|
| Novartis Pharmaceuticals | None | $205 | 9 payments
|
| Aurinia Pharma U.S. | Lupkynis | $168 | 7 payments
|
| Lilly USA | Jardiance | $153 | 7 payments
|
| Travere Therapeutics | None | $142 | 6 payments
|
| Amgen | Tavneos | $138 | 5 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $136 | 7 payments
|
| Fresenius USA Marketing | Velphoro | $91 | 4 payments
|
| Vifor Pharma | Veltassa | $87 | 4 payments
|
| Otsuka America Pharmaceutical | Jynarque | $76 | 4 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $62 | 3 payments
|
| OPKO Pharmaceuticals | Rayaldee | $58 | 2 payments
|
| GlaxoSmithKline | Jesduvroq | $55 | 2 payments
|
| Ardelyx | Ibsrela | $50 | 3 payments
|
| Calliditas Therapeutics US | Tarpeyo | $37 | 2 payments
|
| Alexion Pharmaceuticals | Ultomiris | $27 | 1 payment
|
| Otsuka Pharmaceutical Development & Commercialization | Jynarque | $26 | 1 payment
|
2023: $2,321
| Mallinckrodt Hospital Products | Acthar | $386 | 12 payments
|
| Horizon Therapeutics plc | Krystexxa | $214 | 9 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $213 | 11 payments
|
| Travere Therapeutics | None | $180 | 8 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $149 | 7 payments
|
| Boston Scientific | None | $140 | 1 payment
|
| GlaxoSmithKline | Benlysta | $117 | 5 payments
|
| ANI Pharmaceuticals | Purified Cortrophin Gel | $116 | 5 payments
|
| Vifor Pharma | Veltassa | $104 | 5 payments
|
| Amgen | Tavneos | $103 | 5 payments
|
| Calliditas Therapeutics US | Tarpeyo | $97 | 5 payments
|
| OPKO Pharmaceuticals | Rayaldee | $97 | 4 payments
|
| Aurinia Pharma U.S. | Lupkynis | $75 | 3 payments
|
| Akebia Therapeutics | Auryxia | $61 | 3 payments
|
| Philips Electronics North America | (6292) Avc Undivided | $47 | 1 payment
|
| Kyowa Kirin | Crysvita | $47 | 2 payments
|
| Alexion Pharmaceuticals | Ultomiris | $44 | 2 payments
|
| Ardelyx | Ibsrela | $43 | 2 payments
|
| Novartis Pharmaceuticals | None | $33 | 1 payment
|
| Lilly USA | Jardiance | $23 | 1 payment
|
| Otsuka America Pharmaceutical | Jynarque | $20 | 1 payment
|
| Ascendis Pharma | None | $14 | 1 payment
|
2022: $1,697
| Horizon Therapeutics plc | Krystexxa | $333 | 14 payments
|
| Amgen | Parsabiv | $199 | 11 payments
|
| Mallinckrodt Hospital Products | Acthar | $180 | 4 payments
|
| Exeltis USA | Purified Cortrophin Gel | $168 | 9 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $158 | 8 payments
|
| Bayer HealthCare Pharmaceuticals | Kerendia | $140 | 7 payments
|
| OPKO Pharmaceuticals | Rayaldee | $83 | 4 payments
|
| Vifor Pharma | Veltassa | $83 | 4 payments
|
| Akebia Therapeutics | Auryxia | $82 | 4 payments
|
| Calliditas Therapeutics US | Tarpeyo | $78 | 4 payments
|
| Aurinia Pharma U.S. | Lupkynis | $62 | 3 payments
|
| Fresenius USA Marketing | Velphoro | $47 | 3 payments
|
| Otsuka America Pharmaceutical | Jynarque | $43 | 2 payments
|
| GlaxoSmithKline | Benlysta | $27 | 2 payments
|
| Travere Therapeutics | None | $13 | 1 payment
|
2021: $1,218
| Vifor Pharma | Veltassa | $219 | 11 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $181 | 11 payments
|
| Fresenius USA Marketing | Velphoro | $148 | 8 payments
|
| Horizon Therapeutics plc | Krystexxa | $110 | 4 payments
|
| Mallinckrodt Hospital Products | Acthar | $106 | 4 payments
|
| Otsuka America Pharmaceutical | Jynarque | $87 | 5 payments
|
| Amgen | Parsabiv | $69 | 4 payments
|
| OPKO Pharmaceuticals | Rayaldee | $60 | 4 payments
|
| Alnylam Pharmaceuticals | Oxlumo | $58 | 3 payments
|
| Bayer HealthCare Pharmaceuticals | Kerendia | $48 | 3 payments
|
| GlaxoSmithKline | Benlysta | $43 | 2 payments
|
| Aurinia Pharma U.S. | Lupkynis | $40 | 2 payments
|
| Novartis Pharmaceuticals | Afinitor | $25 | 1 payment
|
| Akebia Therapeutics | Auryxia | $23 | 1 payment
|
2020: $584
| Mallinckrodt Hospital Products | Acthar | $185 | 6 payments
|
| Relypsa | Veltassa | $142 | 7 payments
|
| AstraZeneca Pharmaceuticals LP | Lokelma | $96 | 5 payments
|
| Amgen | Parsabiv | $45 | 3 payments
|
| OPKO Pharmaceuticals | Rayaldee | $33 | 2 payments
|
| Genzyme | Fabrazyme | $25 | 1 payment
|
| Otsuka America Pharmaceutical | Jynarque | $22 | 1 payment
|
| Akebia Therapeutics | Auryxia | $21 | 1 payment
|
| Alnylam Pharmaceuticals | Oxlumo | $15 | 1 payment
|
2019: $966
| Mallinckrodt Enterprises | Acthar | $349 | 11 payments
|
| Relypsa | Veltassa | $181 | 8 payments
|
| Otsuka America Pharmaceutical | Jynarque | $109 | 6 payments
|
| AstraZeneca Pharmaceuticals LP | Lokelma | $95 | 5 payments
|
| OPKO Pharmaceuticals | Rayaldee | $64 | 3 payments
|
| Fresenius USA Marketing | Velphoro | $50 | 3 payments
|
| Amgen | Parsabiv | $44 | 2 payments
|
| Horizon Therapeutics plc | Krystexxa | $39 | 2 payments
|
| Genentech USA | Rituxan | $38 | 2 payments
|
Professional record
- NPI
- 1518173608
- Licence
- PA MT179524
- Trained
- State University of New York at Buffalo School of Medicine, 2002
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 1518173608
- Taxonomy
- Federal specialty code 207RN0300X (207RN0300X); Internal medicine (207R00000X)
- Mailing address
- 7500 Greenway Center Dr, Ste 930, Greenbelt, MD, 20770
- NPI first listed
- 2007-05-15
- NPI last updated
- 2017-02-14
This is when the NPI record was last certified, not a medical board exam.